Objective-Galectin-3 (Gal-3) can affect atherogenesis by multiple mechanisms, but it remains scarcely known whether plasma Gal-3 levels predict cardiovascular events in patients with coronary artery disease. Therefore, we investigated if Gal-3 predicts cardiovascular death in patients with coronary artery disease of the Genetic and ENvironmental factors In Coronary Artery disease study. Approach and Results-In a prospective cohort study, we measured the plasma levels of Gal-3 in 1013 randomly selected patients who underwent coronary angiography and long-term follow-up to assess incident cardiovascular events. The primary end points were (1) cardiovascular death and (2) a composite of cardiovascular death, acute coronary syndrome, and stroke. Secondary end points entailed (1) acute myocardial infarction, (2) stroke, and (3) a composite fatal ischemic event including fatal myocardial infarction and stroke. The effect of Gal-3 on prognosis was assessed using Kaplan-Meier analysis and multivariate Cox's regression. During long-term follow-up (median, 7.2 years), 115 cardiovascular deaths occurred (15.2%), more commonly in the high Gal-3 tertile (25.2%) than in the intermediate and the low tertiles (13.6% versus 7.5%, respectively; P<0.001). The adverse prognostic effect of high Gal-3 was confirmed in subgroup analysis of the patients with angiographically documented coronary artery disease and also of those with a normal left ventricular ejection fraction. At multivariate analysis, Gal-3 was a predictor of cardiovascular mortality (hazard ratio, 1.79; 95% confidence interval, 1.10-2.93; P=0.020) along with age, left ventricular ejection fraction, and coronary atherosclerotic burden. Conclusions-In high cardiovascular risk patients referred for coronary angiography Gal-3 is a strong independent predictor of cardiovascular death. (Arterioscler Thromb Vasc Biol. 2015;35:725-732. The online-only Data Supplement is available with this article at http://atvb.ahajournals.org/lookup/suppl/
G alectin-3 (Gal-3) belongs to a family of soluble β-galactoside binding lectins 1 that reside in the nucleus and cytoplasm of several cell types as well as in the extracellular space. [2] [3] [4] It has multiple actions that can be relevant for promoting vascular damage [5] [6] [7] and cardiovascular fibrosis. 8, 9 Accordingly, in patients with heart failure plasma Gal-3 level has been shown to be the best short-term predictor of events, 10, 11 thus leading to incorporation of this measurement in the current American Heart Association heart failure guidelines for risk stratification purposes of such patients. 12 Some actions of Gal-3, as monocytes chemoattraction, enhancement of phagocytosis, 5, 6 and induction of vascular smooth muscle cells proliferation, 7 can play an important role in atherogenesis. However, in spite of these multiple proatherogenic actions, the role of Gal-3 in atherosclerosis has been scarcely investigated in clinical studies thus far. [13] [14] [15] [16] [17] Therefore, in the prospective branch of the Genetic and ENvironmental factors In Coronary Artery disease (GENICA) study, which enrolled high cardiovascular risk patients referred for coronary angiography for suspected coronary artery disease (CAD), we sought to challenge the hypothesis that plasma Gal-3 levels predict cardiovascular deaths and events during long-term follow-up by giving due consideration to many other cardiovascular risk factors and potential confounders.
Methods
Materials and Methods are available in the online-only Data Supplement. For the study flow diagram, please refer to Figure 1 . March 2015 ATP III (Adult Treatment Panel) criteria, 18 which means they had ≥20% risk of major cardiovascular events at 10 years. Table 1 and Table I in the online-only Data Supplement show their features divided into Gal-3 tertiles. Age, sex, serum glucose, sodium, potassium and creatinine levels, estimated glomerular filtration rate, left ventricular ejection fraction (LVEF), homocysteine, low-density lipoprotein cholesterol, medical history, and use of medications at admission differed significantly across the Gal-3 tertiles.
Results were overall similar when the patients with angiographically demonstrated CAD (n=782; Tables II and III in the online-only Data Supplement) and the patients with CAD and preserved LVEF (n=595; Table 2 and Table IV in the onlineonly Data Supplement) were examined. In these subgroups the only additional differences entailed CAD Duke Index Score and high-density lipoprotein cholesterol in the CAD group and high-density lipoprotein cholesterol in the normal LVEF group.
Regression analysis showed that plasma Gal-3 levels were directly related to sex (β=0.083), body mass index (β=0.134), diuretic therapy (β=0.071), triglycerides (β=0.061), and plasma homocysteine (β=0.109), and inversely related to estimated glomerular filtration rate (β=−0.292), and LVEF (β=−0.128). These variables explained 18% of plasma Gal-3 variance (adjusted R 2 =0.183; F=32.6; P<0.0001; Table 3 ). Gal-3 was significantly associated with the atherosclerotic burden only at univariate analysis (ρ=0.104; P=0.004).
Cardiovascular Events at Follow-Up in the Whole Cohort
Follow-up (median, 7.2 years; range, 1.0-12.7 years) data were available in 75% of the 1013 patients. At multiple regression analysis the cases lost did not differ significantly from those available at follow-up (Table V in the online-only Data Supplement). Among the latter patients, 115 (15.2%) had a cardiovascular death, 212 (28.0%) a major cardiovascular event, and 57 (7.5%) a fatal ischemic event. The major cardiovascular events by Gal-3 tertiles are shown in Figure 2 .
At univariate analysis of the whole cohort, patients in the highest Gal-3 tertile had more cardiovascular deaths (25.2%) than those in the intermediate and in the lower tertiles (13.6% and 7.5%, respectively; P<0.001). They also had higher cardiovascular events (35.0% versus 29.6% versus 21.0%, respectively; P<0.001), and fatal ischemic events (11.8% versus 6.7% versus 4.1%, respectively; P=0.001; Figure 3 and Figures I and II in the online-only Data Supplement).
Cox's multivariate analyses were undertaken because of the imbalanced distribution of risk factors and relevant covariates across Gal-3 tertiles. After these adjustments Gal-3 remained an independent predictor of cardiovascular death (hazard ratio [HR], 1.79; 95% confidence interval [CI], 1.10-2.93; P=0.020), along with age (HR, 1.47; 95% CI, 1.19-1.81; P<0.0001), LVEF (HR, 0.68; 95% CI, 0.57-0.82; P<0.0001), and CAD Duke Index Score (HR, 1.14; 95% CI, 1.03-1.26; P=0.012; Table 4 ).
Gal-3 was not a significant predictor of cardiovascular events according to the P value for significance prespecified for multiple testing ( The Gal-3 cutoff value for optimizing prediction was 16.6 ng/mL (area under the curve [AUC], 0.689; 95% CI, 0.654-0.722; P<0.0001) for cardiovascular death, and 13.9 ng/mL (AUC, 0.595; 95% CI, 0.559-0.630; P<0.0001) for cardiovascular events ( Figure III in the online-only Data Supplement).
Cardiovascular Events at Follow-Up in Patients With CAD
To challenge the robustness of these results, we performed a sensitivity analysis limited to the 782 patients with angiographically documented CAD, 606 (77%) of which had follow-up data available. Of these patients, 80 (13.2%) had a cardiovascular death; 167 (27.7%) had a major cardiovascular event and 45 (7.4%) a fatal ischemic event ( Figure IV in the online-only Data Supplement). At univariate analysis patients in the highest Gal-3 tertile had more cardiovascular deaths (23.0% versus 11.2% versus 6.1%, respectively; P<0.001), cardiovascular events (33.2% versus 29.6% versus 21.0%, respectively; P=0.011), and fatal ischemic events (11.2% versus 7.2% versus 3.8%, respectively; P=0.006) than those in the lower Gal-3 tertiles ( Figure V in the online-only Data Supplement).
After adjustment for relevant covariates Gal-3 remained an independent predictor of cardiovascular death (HR, 1.87; 95% CI, 1.04-3.33; P=0.036), along with age, LVEF, CAD Duke Index Score, history of percutaneous transluminal coronary angioplasty, and digoxin therapy ( Table VIII in death and major cardiovascular events prediction in patients with CAD were 20.3 ng/mL (AUC, 0.703; 95% CI, 0.665-0.739; P<0.0001) and 13.9 ng/mL (AUC, 0.578; 95% CI, 0.537-0.617; P<0.004), respectively. Finally, to address the possibility that our results could be driven by the known adverse prognostic effect of Gal-3 in patients with heart failure, we analyzed only the cohort of subjects with angiographically proven CAD and preserved LVEF (>50%; n=595). Follow-up data were available for 465 patients (78%) and in this group 40 (8.6%) had a cardiovascular death, 106 (22.8%) a major cardiovascular event, and 27 (5.8%) a fatal ischemic event ( Figure VI in the online-only Data Supplement). Consistently with the previous findings the highest Gal-3 tertile patients had more cardiovascular deaths (13.4% versus 8.8% versus 4.3%, respectively; P=0.015) also in this subgroup. Moreover, they showed a nonsignificant trend toward more fatal ischemic events (9.2% versus 5.1% versus 3.0%, respectively; P=0.05) compared with the lower Gal-3 tertiles. Cardiovascular events did not differ significantly (24.1% versus 26.2% versus 19.1%, respectively; P=0.2; Figure 4 ).
Cox regression analysis confirmed that Gal-3 was an independent predictor of cardiovascular death (HR, 3.78; 95% CI, 1.51-9.51; P=0.005) along with CAD Duke Index Score, history of percutaneous transluminal coronary angioplasty, estimated glomerular filtration rate, and digoxin therapy (Table 5) . Moreover, Gal-3 independently predicted fatal ischemic events (HR, 5.44; 95% CI, 1.86-15.93; P=0.002) ( Table IX in the online-only Data Supplement), albeit not cardiovascular events.
Finally, at ROC curves analysis the Gal-3 cutoff value for cardiovascular death prediction was 27.7 ng/mL (AUC, 0.625; 95% CI, 0.579-0.669; P<0.01).
Discussion
This prospective cohort study with a long and comprehensive follow-up showed that plasma Gal-3 level is an independent predictor of cardiovascular mortality in patients with CAD without overt LV dysfunction. This finding extends those obtained in patients with heart failure. 10, 11 
Association of Gal-3 With Coronary Atherosclerosis
Studies on small cohorts comprising variable proportions of patients with CAD previously reported an association of Gal-3 with prevalence of CAD 19 and a borderline significant association with the number of affected vessels. 13, 20 At variance, we found only a weak correlation not confirmed at multivariate analysis, between Gal-3 levels and the angiographically ascertained coronary atherosclerotic burden in this large cohort of patients with CAD.
Considering the blunted development of atherosclerosis found in apolipoprotein E/Gal-3 double knockout mice as compared with apolipoprotein E knockout mice, 21 the multiple proatherogenic actions of Gal-3, 5-7 and the detection of Gal-3 human atherosclerotic plaques, 22 this was an unexpected finding that re-emphasizes the divergence between predictors of CAD and of cardiovascular events (see below).
Prognostic Effect of Gal-3
A major novel accomplishment of this study was the finding that in a cohort of patients at high cardiovascular risk, 18 selected for Results are expressed as mean±SD, absolute numbers (percentage), or median and interquartile range; comparisons across Galectin-3 tertiles were made by ANOVA and Bonferroni tests, after log or square root transformation if needed, or χ 2 , as appropriate. BP indicates blood pressure; BMI, body mass index; CAD, coronary artery disease; EF, ejection fraction; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; K + , potassium; LDL, low-density lipoprotein; LVEF, left ventricular ejection fraction; and Na + , sodium.
Bonferroni test: *I vs II tertile, †II vs III tertile, and ‡I vs III tertile. P<0.05 for significance. suspected CAD, high Gal-3 levels predicted cardiovascular mortality ( Figure 3 ) independently of major risk factors. This contention is strengthened by the improved prediction of cardiovascular death by adding Gal-3 to well-established risk factors, like the coronary atherosclerotic burden, at Cox's regression analysis ( Table 4 ).
The prognostic role of Gal-3 was well documented previously in patients with heart failure, 9 where Gal-3 was identified as the best short-term predictor of cardiovascular events 10 and death 10 both in patients with reduced and with preserved LVEF. 23 Gal-3 was shown to predict all-cause and cardiovascular death, and incident heart failure also in healthy subjects, 19, 24, 25 in patients with peripheral artery disease, 17 and in those with acute coronary syndrome. In the latter, it also predicted hospitalizations for heart failure, 14 reinfarction, 15 heart failure, and cardiovascular mortality. 13, 16 Thus, our findings extend to the patients with CAD, the adverse prognostic role of high Gal-3.
The strong prognostic role of Gal-3 in spite of its weak association with CAD atherosclerotic burden deserves some comments: fatal myocardial infarction and atherothrombotic stroke are known to be triggered by rupture of vulnerable atherosclerotic plaques, which is enhanced by factors activating matrix metalloproteinases. The determinants of plaque destabilization, eg, of cardiovascular events, and of plaque growth, eg, of the atherosclerotic burden, are known to differ although they can overlap. Our present results suggest that Gal-3 can contribute more substantively to plaque destabilization than to plaque growth. Of interest, similar discrepancies between some prognostic determinants and the CAD atherosclerotic burden were previously noted both in the GENICA [26] [27] [28] and in other studies. 29, 30 Figure 2. Cardiovascular events. Cardiovascular (CV) death (top), CV events (middle), and fatal ischemic events (bottom) rate by tertiles of Gal-3 in the whole cohort (the number of events is shown above each column). CV deaths χ 2 =31.9, P<0.001; CV events χ 2 =13.0, P=0.002; and fatal ischemic events χ 2 =10.9, P=0.004. Kaplan-Meier curves show that patients in the third (high) Gal-3 tertile (dashed line) had a significantly higher CV deaths, CV events, and fatal ischemic events than the patients in the second (mid) (dotted line) and first (low) (solid line) Gal-3 tertiles. March 2015
Subgroup Analyses
Given the prognostic impact of Gal-3 in patients with heart failure, 10,23,31 many of which have CAD as underlying cause, it might be argued that the adverse effect of Gal-3 on cardiovascular death incidence in our cohort was because of inclusion of patients with heart failure. This contention was, however, not supported by our findings in a subgroup analysis of the patients with preserved LVEF, where high Gal-3 levels were also associated with higher cardiovascular deaths ( Table 5) .
A sensitivity analysis of the patients with angiographically documented CAD showed a practically identical adverse prognostic effect of Gal-3. Hence, with the strength of a prospective cohort study design and of a large cohort of consecutively enrolled patients, our data demonstrate that Gal-3 predicts cardiovascular mortality in patients with CAD regardless of the presence or absence of left ventricular systolic dysfunction. This finding is at variance with previous reports in the general population, 24 in smaller CAD cohorts, [13] [14] [15] [16] and in a large cohort of patients with angiographically demonstrated CAD. 32 A prognostic role of Gal-3 on nonfatal cardiovascular events could not, however, be confirmed at variance with previous studies, [13] [14] [15] [16] possibly because in those cohorts most of the effect on cumulative end points was driven by heart failure-related events. Another possibility is that adjustment for the Duke CAD Index Score, one of the strongest predictors of cardiovascular events and death in patients with CAD, might have concealed an effect of Gal-3 on these end points in the our study. The use of this index was never exploited previously in studies of Gal-3. 13, 16 
Gal-3 Levels Predictors
Our study allowed identification of sex, body mass index, triglycerides, and estimated glomerular filtration rate as predictors of Gal-3 (Table 3) , which concurs with data in the general population. 24 Additional identified predictors, as diuretic treatment and low LVEF, likely reflect the higher levels of Gal-3 in patients with heart failure. Of note, plasma homocysteine was also found to be associated with plasma Gal-3 (Table 3 ). This could be mediated by either a low glomerular filtration rate or a low LVEF, both of which are related with plasma homocysteine. 33, 34 It is worth mentioning, however, that homocysteine can increase Gal-3 through its effect on nuclear factor-kB, a known inducer of Gal-3. 35, 36 This finding could suggest a beneficial effect of homocysteine-lowering treatment, as folates supplementation, in patients with high Gal-3 levels. Kaplan-Meier curves show that patients in the third (high) Gal-3 tertile (dashed line) had a significantly higher CV deaths than the patients in the second (mid) (dotted line) and first (low) (solid line) Gal-3 tertiles, CV events, and fatal ischemic events were not significantly different across Gal-3 tertiles.
Limitations and Strengths of the Study
Our results pertain to a high-risk population of white patients referred for coronary artery angiography. Therefore, they need to be verified in patient cohorts with different risk profiles and ethnicity. It might also be argued that the loss of 25% of the patients at follow-up could have biased our results. However, a selection bias is unlikely as these cases lost did not differ from those available at follow-up for any baseline features.
Finally, the observational nature of our study does not allow mechanistic insights on how Gal-3 affects outcomes.
In spite of these limitations our conclusions are robust and supported by the strengths of a prospective study design, a large cohort with a long-term follow-up, a comprehensive information on anthropometric, biochemical, and clinical features, and a painstaking assessment of cardiovascular events at follow-up, as well as by sensitivity analyses.
Conclusions
In this prospective cohort study in patients with angiographically demonstrated CAD at high cardiovascular risk Gal-3 was a major predictor of cardiovascular mortality. The robustness of this conclusion was confirmed in patients with preserved LVEF and also after adjustments for several covariates that are known to affect prognosis in patients with CAD. Clinical trials designed to test the effects of Gal-3 inhibitors as modified citrus pectin are therefore warranted to prove causality between Gal-3 and progression/complication of coronary atherosclerosis.
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Table 5. Predictors of Cardiovascular Mortality at Cox Regression Analysis in Patients With CAD and Preserved Left Ventricular Ejection Fraction
CAD indicates coronary artery disease; CI, confidence interval; eGFR, estimated glomerular filtration rate; HR, hazard ratio; LVEF, left ventricular ejection fraction; and PTCA, percutaneous transluminal coronary angioplasty.
